Related Experiment Video
Updated: Aug 14, 2026
10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Small molecule coagulation cascade inhibitors in the clinic
1Wyeth Research, 200 CambridgePark Drive, Cambridge, MA 02140, USA. ESaiah@wyeth.com
Current Topics in Medicinal Chemistry
|December 27, 2005
Summary
Novel anticoagulants, including Factor Xa and thrombin inhibitors, show promise for treating venous thromboembolic disease. These agents may improve treatment adherence and reduce monitoring needs compared to traditional therapies.
Area of Science:
- Pharmacology
- Hematology
- Drug Development
Background:
- Venous thromboembolic disease (VTE), encompassing deep vein thrombosis and pulmonary embolism, contributes significantly to mortality and morbidity.
- Current anticoagulant treatments like unfractionated heparin and warfarin have limitations, leading to underuse in clinical practice.
Purpose of the Study:
- To review the development of novel anticoagulants with improved pharmacological and clinical profiles.
- To highlight the potential benefits of new agents over traditional anticoagulant therapies.
Main Methods:
- Review of advanced small molecule Factor Xa inhibitors and thrombin inhibitors in development.
- Identification of specific drug candidates including DPC-423, razaxaban, and others.
Main Results:
- Novel anticoagulants offer potential benefits such as consistent pharmacological profiles and oral formulations.
- These new agents may decrease the need for routine coagulation monitoring.
Conclusions:
- The development of novel anticoagulants is advancing, with several promising candidates.
- These agents are expected to increase the use and duration of anticoagulation for VTE and simplify long-term management.
More Related Videos
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.